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Smith–Lemli–Opitz syndrome (SLOS; MIM 270400) is an autoso-
mal recessive disease caused by a defect in 7-dehydrocholesterol (7-
DHC) reductase (EC 1.3.1.21), the enzyme that catalyzes the last
step of cholesterol (CHOL) biosynthesis. Patients affected by this dis-
order show a large and variable clinical spectrum with multiple mor-
phogenic and congenital anomalies including internal organ, skeletal
and/or skin abnormalities, growth and mental retardation and behav-
ioral problems. Typically, patients affected by SLOS show an accumu-
lation of 7-DHC and 8-dehydrocholesterol (8-DHC) in blood, and
carry disease-causing mutations in the gene encoding the implicated
enzyme [1–3]. Clinical severity correlates negatively with the CHOL
concentration, and positively with the 7-DHC concentration and the
sum of dehydrocholesterols (DHC; 7-DHC+8-DHC) [2,4]. The DHC
fraction (DHC/total sterols) and DHC/CHOL ratio better express the
systemic sterol abnormality than absolute blood sterol concentrations
[2].
The SLOS incidence is variable and difﬁcult to estimate accurately,
and its exact value is unknown. As recently reported, the SLOS inci-
dence is estimated at one in 15,000–60,000 births in the European
population [4–6] and at one in 60,000 births in the United States
[2]. Based on the allele frequencies and the proportion of the most
frequently occurring mutation (IVS8-1 G>C) observed in various pa-
tient populations, the expected incidence of SLOS in those popula-
tions was calculated and reported to range from 1:1,590 to
1:17,000. The discrepancy between the expected incidence and prev-
alence can be explained only in part by the neonatal and infancy
deaths of the most severely affected children with SLOS and the
under-assessment of mild and atypical cases [7].
Until now, there has been no screening test that could be applied
routinely to the newborn ﬁlter paper specimen. Techniques such as
routine biochemical assays and tandem mass spectrometry have not
been employed successfully. Time-consuming and impractical
methods for high-throughput screening, such as gas chromatography
(GC) of plasma sterol proﬁles, currently are preferred for diagnosis. In
addition, the instability of 7-DHC and 8-DHC is particularly elevated
in dried blood spot (DBS) specimens, which present signiﬁcant prea-
nalytical variability, inﬂuencing the accuracy of results [8–10]. Con-
sidering the clinical importance of implementing a screening
method for CHOL and DHC in DBS, this study aims to standardize
the preanalytical variability of DHC in DBS for detecting SLOS by
using ﬁlter paper impregnated with BHT as an antioxidant.
Samples from SLOS patients (n=5) were obtained during follow-
up of sterol proﬁles. Whole blood was collected into Vacutainer tubes
containing EDTA through venipuncture at pediatric units, and was
sent to our laboratory. All samples analyzed in this study were re-
serve materials that were not needed for further diagnostic investiga-
tions, which prevented the need to take extra materials or a greater
sample volume from patients. The DBS were prepared by spotting0009-8981/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.cca.2011.11.00820 μL of whole blood onto ﬁlter paper (Whatmann 3MM) with and
without BHT. Spots were dried for 3 h, while being protected from di-
rect light, and stored in a desiccant sealed plastic bag at 4 °C until
analysis. Filter paper treatment with BHT was performed with strips
of 6×10.5 cm, which were horizontally immersed in 2.5 mL of
CHCl3 solution containing 0.1 mg/mL BHT. The strip was soaked in
this solution for ≤1 min. After complete absorption of the BHT solu-
tion (about 3.97 μg of BHT per cm2 of ﬁlter paper), the strip was air
dried at room temperature for 30 min while being protected from di-
rect light. For each sample, at least 16 spots were prepared on both
ﬁlter papers (with and without BHT). A 6-mm disc was punched
from the DBS and mixed with 1 mL of 1 N potassium hydroxide in
90% ethanol and 25 μL of cholestane as internal standard (IS,
0.4 mg/mL). The sterols were hydrolyzed for 60 min at 80 °C. After,
the sample was diluted with 1 mL of distilled water and extracted
three times with 1 mL of hexane. The upper organic phases were
pooled and evaporated under N2 ﬂow at 40 °C. The dried residue
was dissolved in 50 μL of CH2Cl2, and 1 μL of this solution was injected
into a GC instrument. All samples were analyzed in duplicate. Sterols
were fractionated with a capillary column (SAC-5, 30 m length,
0.25 mm I.D., 0.25 μm ﬁlm thickness; Supelco, Germany) by a GC sys-
tem equipped with a ﬂame ionization detector (GC-FID, HP-5890,
Agilent Laboratories, CA, USA). The injector and detector tempera-
tures were ﬁxed at 300 °C, and the oven temperature was maintained
at 290 °C. The total run time was 10 min. Sterol concentrations (mg/
dL) were obtained by interpolation of the analyte/IS peak-area ratio
on calibration curves. The relative retention times of chromatograph-
ic peaks of CHOL, 8-DHC, and 7-DHC, compared to IS, were 1.43, 1.46,
and 1.52, respectively. The imprecision of method (CV%), performed
on two levels of the positive plasma pool, for CHOL (24.1 and
40 mg/dL) was 3.9 and 4.3, for 8-DHC (4.4 and 7.6 mg/dL) was 4.2
and 5.1, and for 7-DHC (11.1 and 18 mg/dL) was 5.5 and 5.6,
respectively.
In SLOS patients, the DBS concentration values at baseline (ana-
lyzed within 1 d) ranged, for CHOL, from 10.5 to 56.3 mg/dL (0.27
to 1.46 mmol/L) without BHT and from 9.4 to 56.3 mg/dL (0.24 to
1.46 mmol/L) with BHT; for 8-DHC, from 3.6 to 7.4 mg/dL (0.095
to 0.19 mmol/L) without BHT and from 3.8 to 8.4 mg/dL (0.1 to
0.22 mmol/L) with BHT; and for 7-DHC, from 5.6 to 15.2 mg/dL (0.15
to 0.4 mmol/L) without BHT and from 5.9 to 19.1 mg/dL (0.15 to
0.5 mmol/L) with BHT. The DHC/CHOL ratio ranged from 0.23 to 2.1
without BHT and from 0.24 to 2.2 with BHT.
Table 1 reports the average sterol levels and DHC/CHOL ratios in
DBS without and with BHT obtained after sample storage at 4 °C
over 1 (baseline), 3, 7, 14, 28, or 56 d. In DBS without BHT, a statisti-
cally signiﬁcant decrease from baseline values (based on ANOVA
analysis with Bonferroni posttest correction) was observed, for 7-
DHC, after storage for 21 d (−72.4%), 28 d (−75.5%), or 56 d
(−81.2%); for 8-DHC, after storage for 7 d (−49.6%), 14 d
(−54.3%), 21 d (−63.1%), 28 d (−67.4%), or 56 d (−72.7%). No sig-
niﬁcant changes from baseline values were observed in the 7-DHC
and 8-DHC levels in DBS with BHT. Although the DHC/CHOL ratio
values in DBS without BHT after 56 d of storage revealed a marked
Table 1
Sterol levels and DHC/CHOL ratios in SLOS patients obtained from DBS without and with BHT, the values are reported as averages and standard deviations (SD).
Storage days
1 3 7 14 21 28 56
SLOS DBS (n=5) (mg/dL)a
CHOL no BHT 30.6 (17.6) 29.3 (17.0) 28.5 (15.1) 27.0 (11.4) 25.9 (12.6) 26.8 (12.9) 29.9 (20.6)
CHOL with BHT 30.1 (17.8) 31.3 (18.5) 34.3 (20.5) 31.7 (18.7) 29.2 (17.7) 31.1 (18.7) 29.9 (17.9)
7-DHC no BHT 10.8 (4.4) 7.1 (4.3) 4.8 (4.5) 3.9 (3.8) 3.1 (2.5)b 2.7 (2.0)b 2.0 (1.5)b
7-DHC with BHT 11.4 (5.3) 11.9 (5.2) 12.5 (5.8) 11.6 (5.3) 10.5 (5.1) 11.0 (4.8) 9.3 (3.6)
8-DHC no BHT 5.8 (1.5) 4.3 (1.2) 2.8 (1.2)c 2.5 (1.0)c 2.1 (0.6)c 1.8 (0.5)c 1.5 (0.3)c
8-DHC with BHT 6.2 (1.8) 6.2 (1.7) 6.6 (2.0) 5.9 (1.9) 5.4 (2.0) 5.3 (1.8) 4.5 (1.2)
DHC/CHOL no BHT 0.80 (0.75) 0.58 (0.53) 0.35 (0.28) 0.30 (0.24) 0.28 (0.24) 0.24 (0.22) 0.19 (0.18)
DHC/CHOL with BHT 0.85 (0.78) 0.86 (0.80) 0.82 (0.75) 0.81 (0.76) 0.79 (0.73) 0.78 (0.73) 0.73 (0.72)
a Conversion factors to SI units (mg/dL×Factor=mmol/L) are: 0.0259 for Cholesterol; 0.0260 for 7- and 8-DHC.
b Signiﬁcantly different from storage day 1: pb0.05.
c Signiﬁcantly different from storage day 1: pb0.001.
526 Letter to the editordecrease from baseline (−76%) compared to values obtained in DBS
with BHT (−17.1%), the results were not statistically signiﬁcant
(Fig. 1 in Supplementary ﬁle). For CHOL, after 56 d of storage, no sig-
niﬁcant changes of values compared to baseline were found in DBS
without (−2.1%) or with BHT (−4.8%). Furthermore, the DHC/CHOL
ratio in DBS showed a signiﬁcant negative logarithmic correlation
with the storage time at 4 °C without BHT [y=−0.1482 Ln(x);
r=0.955], and the decreasing rate of the DHC/CHOL ratio was 5-
fold faster than that observed in DBS with BHT [y=−0.0296 Ln(x);
r=0.935].
These data conﬁrm that DHC in DBS are highly unstable and easily
oxidizable. From our experience and according to others, DHC in plas-
ma are relatively stable, but substantial auto-oxidation would be
expected for DHC in plasma adsorbed onto ﬁlter paper and exposed
to air for long periods of time [9,10]. Recently, we have also demon-
strated that the oxidation rate of DHC in erythrocyte membranes
from SLOS patients was at least 2-fold higher than that in plasma
[11]. Based on our results, the antioxidant BHT added to ﬁlter paper
for the preparation of DBS stabilizes the concentration of DHC at
least for two months of storage. This procedure could be adopted to
prevent the potential occurrence of false negative results for the anal-
ysis of sterols in DBS using gas chromatography or other methods.
In summary, considering that SLOS is the most frequent CHOL bio-
synthesis defect, and its prevalence has not yet been accurately deter-
mined, DBS treated with BHT could be recommended for the
measurement of DHC in DBS by using a screening method.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.cca.2011.11.008.
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